Molecular diagnostics company Novacyt S.A. (EURONEXT GROWTH: ALNOV) (AIM: NCYT) announced on Monday that, further to its 23 February 2026 notification, its wholly owned subsidiary, Novacyt Holdings UK Limited, has completed the acquisition of Southern Cross Diagnostics Pty Ltd.

The company stated that further details regarding a Preferential Subscription Rights issue will be announced immediately following this update.

Novacyt S.A. is focused on genomic medicine, developing, manufacturing and commercialising molecular assays and instrumentation. Its operations span human health, animal health and environmental sectors, delivering end-to-end solutions from sample to result.

The Group is structured across three segments: Clinical, offering in vitro diagnostic products and services across reproductive health, precision medicine and infectious diseases; Instrumentation, including DNA sample preparation platforms and real-time quantitative PCR systems; and Research Use Only, providing qPCR assay development and pharmaceutical research services, including whole genome and whole exome sequencing.

Headquartered in Le Vésinet, France, Novacyt S.A. maintains offices in the UK, Singapore, the US and Canada, with a commercial presence in over 65 countries.